The North America Biodefense Market would witness market growth of 5% CAGR during the forecast period (2020-2026). Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.
Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks. Some of the past incidents of bioterrorism carried out by viral agents like botulism, anthrax, and smallpox, have made biodefense a significant focus area for research by countries to defend against bioterrorism.
Governments’ agencies were forced to develop and strategize biodefense programs due to repeated outbreaks of the Ebola and Zika virus, hence aid in planning and responding during future outbreaks. In 2018, the U.S. government issued the National Biodefense Strategy to manage the threats of biological incidents by identifying and preventing bio treats at its initial stage, encouraging biomedical innovation, and enhancing emergency response.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Biodefense Market in North America is expected to register a CAGR of 5% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/nuclear
- Other Products
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Biodefense Market, by Product
1.4.2 North America Biodefense Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Approvals
3.1.3 Acquisition and Mergers
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
Chapter 4. North America Biodefense Market by Product
4.1 North America Anthrax Market by Country
4.2 North America Smallpox Market by Country
4.3 North America Botulism Market by Country
4.4 North America Radiation/nuclear Market by Country
4.5 North America Other Product Market by Country
Chapter 5. North America Biodefense Market by Country
5.1 US Biodefense Market
5.1.1 US Biodefense Market by Product
5.2 Canada Biodefense Market
5.2.1 Canada Biodefense Market by Product
5.3 Mexico Biodefense Market
5.3.1 Mexico Biodefense Market by Product
5.4 Rest of North America Biodefense Market
5.4.1 Rest of North America Biodefense Market by Product
Chapter 6. Company Profiles
6.1 Xoma Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Altimmune, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Acquisition and Mergers:
6.2.4.2 Partnerships, Collaborations, and Agreements:
6.3 Emergent BioSolutions, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Research & Development Expense
6.3.4 Recent strategies and developments:
6.3.4.1 Acquisition and Mergers:
6.3.4.2 Partnerships, Collaborations, and Agreements:
6.4 Dynavax Technologies Corporation
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expense
6.5 SIGA Technologies, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.5.4.2 Approvals:
6.6 Elusys Therapeutics, Inc.
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Approvals:
6.7 Ichor Holdings, Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.8 Cleveland BioLabs, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.8.4 Recent strategies and developments:
6.8.4.1 Partnerships, Collaborations, and Agreements:
6.9 Bavarian Nordic A/S
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.9.5.2 Approvals:
6.10. Alnylam Pharmaceuticals, Inc.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Research & Development Expense
TABLE 1 North America Biodefense Market, 2016 - 2019, USD Million
TABLE 2 North America Biodefense Market, 2020 - 2026, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bio-defense Market
TABLE 4 Approvals– Bio-defense Market
TABLE 5 Acquisition and Mergers– Bio-defense Market
TABLE 6 North America Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 7 North America Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 8 North America Anthrax Market by Country, 2016 - 2019, USD Million
TABLE 9 North America Anthrax Market by Country, 2020 - 2026, USD Million
TABLE 10 North America Smallpox Market by Country, 2016 - 2019, USD Million
TABLE 11 North America Smallpox Market by Country, 2020 - 2026, USD Million
TABLE 12 North America Botulism Market by Country, 2016 - 2019, USD Million
TABLE 13 North America Botulism Market by Country, 2020 - 2026, USD Million
TABLE 14 North America Radiation/nuclear Market by Country, 2016 - 2019, USD Million
TABLE 15 North America Radiation/nuclear Market by Country, 2020 - 2026, USD Million
TABLE 16 North America Other Product Market by Country, 2016 - 2019, USD Million
TABLE 17 North America Other Product Market by Country, 2020 - 2026, USD Million
TABLE 18 North America Biodefense Market by Country, 2016 - 2019, USD Million
TABLE 19 North America Biodefense Market by Country, 2020 - 2026, USD Million
TABLE 20 US Biodefense Market, 2016 - 2019, USD Million
TABLE 21 US Biodefense Market, 2020 - 2026, USD Million
TABLE 22 US Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 23 US Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 24 Canada Biodefense Market, 2016 - 2019, USD Million
TABLE 25 Canada Biodefense Market, 2020 - 2026, USD Million
TABLE 26 Canada Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 27 Canada Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 28 Mexico Biodefense Market, 2016 - 2019, USD Million
TABLE 29 Mexico Biodefense Market, 2020 - 2026, USD Million
TABLE 30 Mexico Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 31 Mexico Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 32 Rest of North America Biodefense Market, 2016 - 2019, USD Million
TABLE 33 Rest of North America Biodefense Market, 2020 - 2026, USD Million
TABLE 34 Rest of North America Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 35 Rest of North America Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 36 Key Information –Xoma Corporation
TABLE 37 Key Information – Altimmune, Inc.
TABLE 38 Key Information – Emergent BioSolutions, Inc.
TABLE 39 Key Information – Dynavax Technologies Corporation
TABLE 40 Key Information – SIGA Technologies, Inc.
TABLE 41 key information – Elusys Therapeutics, Inc.
TABLE 42 key Information – Ichor Holdings, Ltd.
TABLE 43 Key Information – Cleveland BioLabs, Inc.
TABLE 44 key information – Bavarian Nordic A/S
TABLE 45 Key Information – Alnylam Pharmaceuticals, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
FIG 4 Recent strategies and developments: Altimmune, Inc.
FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.